BrightGene Total Revenue from 2010 to 2025

Stocks . China . 
Stock . BrightGene Bio Medical
688166 Stock   30.92  1.21  4.07%   
BrightGene Bio's Total Revenue is increasing over the years with slightly volatile fluctuation. Total Revenue is expected to dwindle to about 751.2 M. Total Revenue is the total amount of income generated by the sale of goods or services related to BrightGene Bio's primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2019-06-30
Previous Quarter
317.6 M
Current Value
319.1 M
Quarterly Volatility
69.5 M
 
Covid
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
  
This module can also supplement various BrightGene Bio Technical models . Check out the analysis of BrightGene Bio Correlation against competitors.

Currently Active Assets on Macroaxis

FFord Motor
GMGeneral Motors
SSentinelOne
GOOGAlphabet Inc Class C
WDWalker Dunlop

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY